Skip to search formSkip to main contentSkip to account menu

R1626

Known as: R 1626, R-1626 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

balapiravir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection
Review
2010
Review
2010
The standard treatment of HCV infection with pegylated interferon-a2a or -a2b and ribavirin is effective in <50%
The standard treatment of HCV infection with pegylated interferon-a2a or -a2b and ribavirin is effective in <50% of HCV genotype… 
Review
2009
Review
2009
Approaches for the development of antiviral compounds: the case of hepatitis C virus.
Traditional methods for general drug discovery typically include evaluating random compound libraries for activity in relevant… 
2009
2009
Chemical stability of 4′-azidocytidine and its prodrug balapiravir
Background: R1479, a 4′-azidocytidine nucleoside analog, was developed for the treatment of Hepatitis C virus infection… 
2008
2008
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability.
The nucleoside analog R1479 is a potent and highly selective inhibitor of NS5b-directed hepatitis C virus (HCV) RNA polymerase in… 
2008
2008
High relapse rate seen at week 72 for patients treated with R1626 combination therapy
2008
2008
21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO
2008
2008
R1626, interféron pégylé et ribavirine, la trithérapie de demain pour l’hépatite C ?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)